DOKOTA BROWN: Open Payments
NPI 1598271777 · KENOSHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 26 payments from 12 companies in 2025. Trend: 2023 $138 · 2024 $0 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 7 | $328 |
| Gilead Sciences, Inc. | 2 | $140 |
| Lilly USA, LLC | 1 | $123 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| Indivior Inc. | 3 | $80 |
| Alkermes, Inc. | 2 | $51 |
| Braeburn Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: Auvelity, Epclusa, ZEPBOUND, CAPLYTA, SUBLOCADE, VIVITROL, BRIXADI, FANAPT.
Industry payments across WI — which companies pay providers there.
